Contrary to the pro-oncogenic role of the activatory Gα13 R200K mutation in bladder cancer, B cell lymphomas have been reported to be driven by inhibitory mutations in GNA13 or RHOA21,22. This evidence concerns the gene GNA13 and B-cell non-Hodgkin lymphoma.